RecallRadar

FDA Drug recall D-0354-2023

Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50…

On 2023-03-08 the FDA classified a Class III recall of Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50… by Sciegen Pharmaceuticals, citing presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0354-2023
ClassificationClass III
Statusterminated
Initiated2023-02-17
Published2023-03-08
Last updated2026-09-13 11:52 UTC
CompanySciegen Pharmaceuticals
DistributionUS

Product

Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.

Reason

Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

Identifiers

ndc50228-177-30
ndc50228-177-01
ndc50228-177-05
ndc50228-178-30
ndc50228-178-01
ndc50228-178-05
code_infoLot # G177092, Exp. 11/24

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0354-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.